Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.

Breast Cancer Res 2019 02 22;21(1):30. Epub 2019 Feb 22.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Background: The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies. However, whether AR expression modifies the efficacy of selective ER modulators or aromatase inhibitors for ER+ cancers remains unclear.

Methods: We evaluated the prognostic and predictive value of AR expression among 3021 postmenopausal ER+ breast cancer patients in the Breast International Group (BIG) trial 1-98. The BIG 1-98 study was a four-armed, double-blind, phase III randomized clinical trial that compared 5 years of tamoxifen or letrozole monotherapy, or sequences of 2 years and 3 years treatment with one drug and then the other. AR expression was measured by immunohistochemistry and the percentage of AR-positive nuclei was quantified. The association between AR expression and prognosis was evaluated using Cox proportional hazards models. Continuous AR-by-treatment interactions were assessed using Subpopulation Treatment Effect Pattern Plots (STEPP).

Results: Eighty-two percent of patients had AR+ (≥ 1%) tumors. Patients with AR+ cancers were more likely to have smaller, lower-grade tumors, with higher expression of ER and PR. AR expression was not associated with breast cancer-free interval (BCFI) (415 events) over a median 8.0 years of follow-up (p = 0.12, log-rank test). In multivariable-adjusted models, AR expression was not associated with BCFI (HR = 1.07, 95% CI 0.83-1.36, p = 0.60). The letrozole versus tamoxifen monotherapy treatment effect did not significantly differ for AR+ tumors (HR = 0.63, 95% CI 0.44-0.75, p = 0.003) and AR- tumors (HR = 0.39, 95% CI 0.21-0.72, p = 0.002) (p-heterogeneity = 0.16). STEPP analysis also suggested no heterogeneity of the treatment effect across the continuum of AR expression.

Conclusions: AR expression was not associated with prognosis, nor was there heterogeneity of the letrozole versus tamoxifen treatment effect by AR expression. These findings suggest that AR expression may not be an informative biomarker for the selection of adjuvant endocrine therapy for postmenopausal women with ER+ breast cancers.

Trial Registration: , NCT00004205, Registered 27 January 2003-Retrospectively registered, .

Download full-text PDF

Source Listing
February 2019
4 Reads

Publication Analysis

Top Keywords

expression associated
breast cancer
trial 1-98
breast international
er+ breast
letrozole versus
versus tamoxifen
estrogen receptor-positive
postmenopausal women
patients ar+
prognostic predictive
androgen receptor
international group
cancers smaller
smaller lower-grade
≥ 1% tumors


(Supplied by CrossRef)
Article in Lancet
Early Breast Cancer Trialists’ Collaborative Group et al.
Lancet 2005
Article in Mod Pathol
LC Collins et al.
Mod Pathol 2011
Article in Fertil Steril
C Dimitrakakis et al.
Fertil Steril 2002
Article in BMC Cancer
LO Gonzalez et al.
BMC Cancer 2008
Article in Mod Pathol
LA Niemeier et al.
Mod Pathol 2010
Article in Clin Cancer Res
C Ricciardelli et al.
Clin Cancer Res 2018
Article in Oncotarget
A Majumder et al.
Oncotarget 2017
Article in Mol Endocrinol
TE Hickey et al.
Mol Endocrinol 2012
Article in Clin Investig
E Lim et al.
Clin Investig 2012
Article in Oncogene.
AS Doane et al.
Oncogene. 2006
Article in Clin Cancer Res
I Bozovic-Spasojevic et al.
Clin Cancer Res 2017

Similar Publications